Abstract: A field effect transistor includes a source-side doped well, a drift-region well, a source region, a drain region; a shallow trench isolation structure including a first portion overlying the drift-region well and laterally spaced from the source-side doped well; a gate dielectric layer; a gate electrode overlying the gate dielectric layer; and a proximal doped layer stack embedded within the drift-region well and interposed between the source-side doped well and the first portion of the shallow trench isolation structure. Proximal doped semiconductor layers of the proximal doped layer stack have different average atomic concentrations of dopants of the second conductivity type.

Abstract: A method of inhibiting oral pathogens comprising administering to a subject in need thereof an effective amount of Lactobacillus strain-containing food composite, medical composite and oral cleaning composite. The food composite, medical composite and oral cleaning composite comprises at least one Lactobacillus strain, which is at least one isolated Lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain, CCTCC NO: M2011124; Lactobacillus salivarius subsp. salicinius AP-32 strain, CCTCC NO: M2011127; Lactobacillus reuteri GL-104 strain, CCTCC NO: M209138; Lactobacillus paracasei GL-156 strain, CCTCC NO: M2014590; Lactobacillus helveticus RE-78 strain, CGMCC No. 13513; Lactobacillus rhamnosus CT-53 strain, CCTCC NO: M2011129; and Lactobacillus paracasei ET-66 strain, CGMCC No. 13514, which are respectively preserved in China Center for Type Culture Collection (CCTCC) and China General Microbiological Culture Collection Center (CGMCC).

Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).

Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).

Abstract: A power semiconductor device includes a semiconductor substrate with an edge termination region between an active region and a lateral rim. Non-metallic electrodes extend in the edge termination region on a front side of the substrate, and include at least three spaced apart non-metallic electrodes. One non-metallic electrode is an inner non-metallic electrode having an inner edge. Another non-metallic electrode is an outer non-metallic electrode having an outer edge. The shortest distance between the inner edge of the inner non-metallic electrode and the outer edge of the most non-metallic electrode is defined as distance p. Each non-metallic electrode is electrically connected to a respective doping region of the substrate by at least two respective metallic plugs each extending through a respective first opening formed in an electrically insulating bottom layer. The shortest distance d between any two metallic plugs of different non-metallic electrodes is larger than the distance p.

Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

Abstract: A vaginitis pathogen-inhibiting composition comprises a fermentate of lactic acid bacteria, which is generated by jointly fermenting a lactic acid bacteria strain and Streptococcus thermophilus in a medium containing at least one of milk, powdered milk, and casein. The lactic acid bacteria strain includes an AP-32 strain of Lactobacillus salivarius subsp. Salicinius; an F-1 strain of Lactobacillus rhamnosus; a GL-165 strain of Lactobacillus rhamnosus; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a Bv-889 strain of Bifidobacterium breve; or combinations thereof. The above-mentioned fermentate of the lactic acid bacteria strain can inhibit growth of vaginitis pathogens and may be in form of a food composition, a pharmaceutical composition, or a vagina-cleaning composition.

Abstract: An isolated lactic acid bacterium strain or fermentation metabolite thereof has an anti-oxidant function and is in form of a food composition or a pharmaceutical composition, wherein the isolated lactic acid bacterium strain comprises at least one of an OLP-01 strain of Bifidobacterium longum subsp. longum; a Bv-889 strain of Bifidobacterium breve; a BLI-02 strain of Bifidobacterium longum subsp. infantis; a CP-9 strain of Bifidobacterium animalis subsp. lactis; a Bf-688 strain of Bifidobacterium bifidum; a GL-104 strain of Lactobacillus reuteri; an AP-32 strain of Lactobacillus salivarius subsp. salicinius; and a bv-77 strain of Lactobacillus rhamnosus.

Abstract: A fermentation metabolite generated by an isolated lactic acid bacterium including at least one of a Bv-889 strain of Bifidobacterium breve, a BLI-02 strain of Bifidobacterium longum subsp. infantis, a CP-9 strain of Bifidobacterium animalis subsp. lactis, a Bf-688 strain of Bifidobacterium bifidum, an AP-32 strain of Lactobacillus salivarius subsp. salicinius, and a GL-156 strain of Lactobacillus paracasei. The fermentation metabolite of the abovementioned strains have a skin-whitening effect and is in form of a food composition or a cosmeceutical composition.

Abstract: A semiconductor device includes a transistor. The transistor includes a drift region of a first conductivity type in a semiconductor substrate having a first main surface, a body region of a second conductivity type between the drift region and the first main surface, and a plurality of trenches in the first main surface and patterning the semiconductor substrate into a plurality of mesas including a first mesa and a dummy mesa. The plurality of trenches includes at least one active trench. The first mesa is arranged at a first side of the active trench, and the dummy mesa is arranged at a second side of the active trench. A gate electrode is arranged in the active trench, and a source region of the first conductivity type is in the first mesa. A one-sided channel of the transistor is configured to be formed in the first mesa.

Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

Abstract: An isolated lactic acid bacteria strain: Bifidobacterium longum subsp. longum OLP-01 strain for increasing exercise performance and ameliorating fatigue is disclosed. A variety of animal experiments have proved that OLP-01 not only effectively improves muscle strength and swimming endurance but also significantly reduces fatigue-related biochemical indicators, including blood lactate, blood urea nitrogen and the activity of creatine kinase.

Abstract: At least one isolated lactic acid bacteria strains selected from the following: TSP05 (Lactobacillus plantarum), TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri) is provided. The above-mentioned active or inactive lactic acid bacteria strains have a function of hepatoprotection and is used in a form of a food composition or a pharmaceutical composition.

Abstract: A food composition and pharmaceutical composition with strains of lactic acid bacteria for reducing blood uric acid concentration are provided, comprising at least one or two isolated lactic acid bacteria strains selected from the following two: TSF331 (Lactobacillus fermentum) and TSR332 (Lactobacillus reuteri).

Abstract: A method of inhibiting oral pathogens comprising administering to a subject in need thereof an effective amount of lactobacillus strain-containing food composite, medical composite and oral cleaning composite. The food composite, medical composite and oral cleaning composite comprises at least one lactobacillus strain, which is at least one isolated lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain, CCTCC NO: M2011124; Lactobacillus salivarius subsp. salicinius AP-32 strain, CCTCC NO: M2011127; Lactobacillus reuteri GL-104 strain, CCTCC NO: M209138; Lactobacillus paracasei GL-156 strain, CCTCC NO: M2014590; Lactobacillus helveticus RE-78 strain, CGMCC No. 13513; Lactobacillus rhamnosus CT-53 strain, CCTCC NO: M2011129; and Lactobacillus paracasei ET-66 strain, CGMCC No. 13514, which are respectively preserved in China Center for Type Culture Collection (CCTCC) and China General Microbiological Culture Collection Center (CGMCC).

Abstract: A power semiconductor device includes a semiconductor substrate with an edge termination region between an active region and a lateral rim. Non-metallic electrodes extend in the edge termination region on a front side of the substrate, and include at least three spaced apart non-metallic electrodes. One non-metallic electrode is an inner non-metallic electrode having an inner edge. Another non-metallic electrode is an outer non-metallic electrode having an outer edge. The shortest distance between the inner edge of the inner non-metallic electrode and the outer edge of the most non-metallic electrode is defined as distance p. Each non-metallic electrode is electrically connected to a respective doping region of the substrate by at least two respective metallic plugs each extending through a respective first opening formed in an electrically insulating bottom layer. The shortest distance d between any two metallic plugs of different non-metallic electrodes is larger than the distance p.

Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

Abstract: A semiconductor device includes a transistor. The transistor includes a drift region of a first conductivity type in a semiconductor substrate having a first main surface, a body region of a second conductivity type between the drift region and the first main surface, and a plurality of trenches in the first main surface and patterning the semiconductor substrate into a plurality of mesas including a first mesa and a dummy mesa. The plurality of trenches includes at least one active trench. The first mesa is arranged at a first side of the active trench, and the dummy mesa is arranged at a second side of the active trench. A gate electrode is arranged in the active trench, and a source region of the first conductivity type is in the first mesa. A one-sided channel of the transistor is configured to be formed in the first mesa.

Abstract: A semiconductor body having first and second vertically spaced apart surfaces is formed. A gate trench that vertically extends from the first surface of the semiconductor body towards the second surface is formed. A gate electrode and a gate dielectric are formed in the gate trench. The gate dielectric electrically insulates the gate electrode from adjacent semiconductor material. A doped superjunction region vertically extending from a bottom of the gate trench towards the second surface of the semiconductor body is formed. The doped superjunction region includes first, second, and third doped pillars vertically extending from the first surface of the first semiconductor layer and directly adjoining one another. The second pillar is laterally centered between the first and third pillars and has an opposite conductivity type as the first and third pillars.